iQure Pharma and University of Padova Unite for Groundbreaking CNS Research iQure Pharma partners with the University of Padova to advance its CNS disorder research, focusing on restoring glutamate balance for innovative treatments.

iQure Pharma and University of Padova Unite for Groundbreaking CNS Research #United_States #Princeton,_NJ #CNS_disorders #iQure_Pharma #University_of_Padova

iQure Pharma Achieves US Patent for Innovative CNS Drug iQ-007 iQure Pharma has secured a US patent for iQ-007, a groundbreaking drug designed to restore glutamate balance for CNS disorders, aiming to revolutionize treatment for epilepsy.

iQure Pharma Achieves US Patent for Innovative CNS Drug iQ-007 #United_States #Princeton #CNS_disorders #iQure_Pharma #iQ-007

Cognitive Research Corporation Names Jason Casarella as New Chief Commercial Officer Cognitive Research Corporation has appointed Jason Casarella, an industry veteran, as their new Chief Commercial Officer to boost CNS clinical trials.

Cognitive Research Corporation Names Jason Casarella as New Chief Commercial Officer #United_States #St._Petersburg #CNS_disorders #Cognitive_Research #Jason_Casarella

Apertura Gene Therapy Partners To Enhance CNS Treatment with Innovative Capsids Apertura Gene Therapy has secured licensing agreements to leverage its novel AAV capsid technology, promising a breakthrough in CNS therapies.

Apertura Gene Therapy Partners To Enhance CNS Treatment with Innovative Capsids #USA #New_York #CNS_disorders #Apertura_Gene_Therapy #TfR1_CapX

iQure Pharma Welcomes Prof. Iris Loew-Friedrich as New Clinical and R&D Advisor iQure Pharma announces the appointment of Prof. Iris Loew-Friedrich as Clinical and R&D Advisor, enhancing its expertise in CNS disorder treatment research.

iQure Pharma Welcomes Prof. Iris Loew-Friedrich as New Clinical and R&D Advisor #USA #Princeton #CNS_disorders #iQure_Pharma #Iris_Loew-Friedrich

EQT Life Sciences Boosts Noema Pharma's Series B Funding to CHF 130 Million EQT Life Sciences leads a Series B funding extension for Noema Pharma, increasing investment total to CHF 130 million, targeting CNS disorders.

EQT Life Sciences Boosts Noema Pharma's Series B Funding to CHF 130 Million #Switzerland #EQT_Life_Sciences #Noema_Pharma #CNS_disorders #Basel